A citation-based method for searching scientific literature

Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, Kristian Reich, Atul A Deodhar, Iain B McInnes, Brian Porter, Ayan Das Gupta, Luminita Pricop, Todd Fox. Ann Rheum Dis 2019
Times Cited: 97







List of co-cited articles
1266 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
975
53

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
576
40

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
36

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
526
31

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R Targan, Brian Feagan, Severine Vermeire, Remo Panaccione, Gil Y Melmed, Carol Landers, Dalin Li, Chris Russell, Richard Newmark, Nan Zhang,[...]. Am J Gastroenterol 2016
210
30

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
486
27

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados,[...]. Ann Rheum Dis 2017
795
26

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
141
24


Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
219
18

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
306
17

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Lai-Shan Tam, Carlo Salvarani, Tae-Hwan Kim, Alan Solinger, Yakov Datsenko,[...]. Ann Rheum Dis 2018
177
16

Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.
Jingzhou Wang, Arvin Bhatia, Noa Krugliak Cleveland, Nina Gupta, Sushila Dalal, David T Rubin, Atsushi Sakuraba. ACG Case Rep J 2018
40
40

Paradoxical gastrointestinal effects of interleukin-17 blockers.
Marine Fauny, David Moulin, Ferdinando D'Amico, Patrick Netter, Nadine Petitpain, Djesia Arnone, Jean-Yves Jouzeau, Damien Loeuille, Laurent Peyrin-Biroulet. Ann Rheum Dis 2020
66
24

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.
Jacob S Lee, Cristina M Tato, Barbara Joyce-Shaikh, Muhammet F Gulen, Corinne Cayatte, Yi Chen, Wendy M Blumenschein, Michael Judo, Gulesi Ayanoglu, Terrill K McClanahan,[...]. Immunity 2015
411
15

Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice.
Atsuhiro Ogawa, Akira Andoh, Yoshio Araki, Tadao Bamba, Yoshihide Fujiyama. Clin Immunol 2004
360
15

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
Jonathan P Sherlock, Barbara Joyce-Shaikh, Scott P Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M Gorman, Edward P Bowman, Terrill K McClanahan, Jennifer H Yearley,[...]. Nat Med 2012
694
14

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
495
14

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Denis Poddubnyy, Paul Emery, Eumorphia M Delicha, Zsolt Talloczy, Brian Porter. Rheumatology (Oxford) 2019
72
18

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter. Arthritis Res Ther 2017
111
13

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.
María José Fobelo Lozano, Reyes Serrano Giménez, Manuel Castro Fernández. J Crohns Colitis 2018
35
37

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
473
13

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
142
13

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Dominique Baeten, Joachim Sieper, Paul Emery, Aimee Readie, Ruvie Martin, Shephard Mpofu, Hanno B Richards. Ann Rheum Dis 2017
161
12

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.
Joseph R Maxwell, Yu Zhang, William A Brown, Carole L Smith, Fergus R Byrne, Mike Fiorino, Erin Stevens, Jeannette Bigler, John A Davis, James B Rottman,[...]. Immunity 2015
208
12

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Megan Hohenberger, Leah A Cardwell, Elias Oussedik, Steven R Feldman. J Dermatolog Treat 2018
93
12

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
Atul Deodhar, Lianne S Gensler, Joachim Sieper, Michael Clark, Cesar Calderon, Yuhua Wang, Yiying Zhou, Jocelyn H Leu, Kim Campbell, Kristen Sweet,[...]. Arthritis Rheumatol 2019
150
12

A protective function for interleukin 17A in T cell-mediated intestinal inflammation.
William O'Connor, Masahito Kamanaka, Carmen J Booth, Terrence Town, Susumu Nakae, Yoichiro Iwakura, Jay K Kolls, Richard A Flavell. Nat Immunol 2009
589
12

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
553
12

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Atul Deodhar, Désirée van der Heijde, Lianne S Gensler, Tae-Hwan Kim, Walter P Maksymowych, Mikkel Østergaard, Denis Poddubnyy, Helena Marzo-Ortega, Louis Bessette, Tetsuya Tomita,[...]. Lancet 2020
81
14

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
Dean Ehrlich, Nimah Jamaluddin, Joseph Pisegna, David Padua. Case Rep Gastrointest Med 2018
19
57

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, Craig L Leonardi, Andrew Blauvelt, Tsen-Fang Tsai, Yankun Gong, Jiaqing Huang, Charis Papavassilis, Todd Fox. J Am Acad Dermatol 2016
193
11

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
278
11

Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study.
Alexander Egeberg, Jacob P Thyssen, Johan Burisch, Jean-Frederic Colombel. J Invest Dermatol 2019
25
44

Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?
Walter Fries, Alessandra Belvedere, Maria Cappello, Ambrogio Orlando, Gianluca Trifirò. Clin Drug Investig 2019
16
68

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
108
11

Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba. Aliment Pharmacol Ther 2019
28
39

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
269
11

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
867
10

Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model.
Liesbet Van Praet, Filip E Van den Bosch, Peggy Jacques, Philippe Carron, Lennart Jans, Roos Colman, Elien Glorieus, Harald Peeters, Herman Mielants, Martine De Vos,[...]. Ann Rheum Dis 2013
155
10

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Atul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, Carlo Salvarani, Eric Lespessailles, Proton Rahman, Pentti Järvinen, Juan Sanchez-Burson, Karl Gaffney, Eun Bong Lee,[...]. Arthritis Rheumatol 2019
90
11


Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin,[...]. J Am Acad Dermatol 2017
60
16

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D G Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou,[...]. Ann Rheum Dis 2018
119
10

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Michael M Ward, Atul Deodhar, Lianne S Gensler, Maureen Dubreuil, David Yu, Muhammad Asim Khan, Nigil Haroon, David Borenstein, Runsheng Wang, Ann Biehl,[...]. Arthritis Rheumatol 2019
230
10

Psoriasis.
Wolf-Henning Boehncke, Michael P Schön. Lancet 2015
10

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.
Johan Burisch, Wolfgang Eigner, Stefan Schreiber, Daniel Aletaha, Wolfgang Weninger, Michael Trauner, Walter Reinisch, Neeraj Narula. PLoS One 2020
16
62

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
79
12

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Andrew Blauvelt, Andrea Chiricozzi. Clin Rev Allergy Immunol 2018
235
10

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
Richard H Duerr, Kent D Taylor, Steven R Brant, John D Rioux, Mark S Silverberg, Mark J Daly, A Hillary Steinhart, Clara Abraham, Miguel Regueiro, Anne Griffiths,[...]. Science 2006
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.